Texas named a best state for remote work

work from home, y'all

A new list Texas at No. 6 among the best states for people seeking remote jobs. Photo vie Getty Images

Economic development boosters regularly tout Texas as a business-friendly state. Now, they can add another positive attribute: Texas ranks as one of the top remote-work-friendly states in the U.S.

A new list from the CareerCloud career platform puts Texas at No. 6 among the best states for people seeking remote jobs. Utah leads the ranking, followed by Colorado, the District of Columbia, Washington, and Virginia.

Helping lift Texas toward the top of the ranking is its No. 3 spot among the states projected to see the most growth (26 percent) in remote-friendly jobs from 2018 to 2028. Utah ranks first (41.7 percent) and Colorado ranks second (30.8 percent).

CareerCloud judged states on two other factors: broadband internet access, with Texas holding the No. 23 spot, and employment per 1,000 remote-friendly jobs, with Texas at No. 24.

These are the 14 jobs that CareerCloud deemed remote-friendly:

  • Accountant
  • Actuary
  • Computer network architect
  • Computer systems manager
  • Computer systems analyst
  • Database administrator
  • Information security analyst
  • Management analyst
  • Market research analyst
  • Marketing manager
  • Mathematician
  • Software developer
  • Statistician
  • Web developer

A list published last year by TheStreet, an investment website, backs up Texas' position in the CareerCloud ranking. The Street names nine places in Texas among the 30 best U.S. cities for remote work during the pandemic: El Paso, Plano, Garland, Corpus Christi, San Antonio, Austin, Fort Worth, Arlington, and Dallas. Houston didn't make the cut.

By contrast, not a single city in Texas appears on a list published by Money Crashers, a personal finance website, of the 20 best places in the U.S. to live and work remotely in 2021. Likewise, Livability.com leaves Texas cities off its list of the country's top 10 remote-ready cities for 2021.

A March 21 post authored by Tory Gattis, editor of the Houston Strategies blog and founding senior fellow at the Center for Opportunity Urbanism, makes the case for and against Houston as a remote-work hub.

Gattis lays out these factors in favor of Houston as a remote-friendly place:

  • Most affordable global city in the U.S., offering big-city amenities at a reasonable cost
  • Lots of Houston ex-pats who might come home to be closer to family and friends
  • Strong community culture for such a large, diverse city
  • Healthy immigrant ecosystem

According to Gattis, these are some of the unfavorable factors for Houston as a remote-friendly spot:

  • Not a classic "lifestyle" destination like Austin, Denver, or Miami
  • Big-city problems like traffic and crime
  • Climate susceptible to hurricanes, flooding, heat, and humidity

"Overall," Gattis writes, "I'd say we're likely to come out fairly well — not as good as the popular lifestyle cities, but much better than the unaffordable superstar cities like SF and NYC."

Could tapping into 401k investment be a gamechanger for Houston startup funding? Photo via Getty Images

Expert: New 401k investment options would spur Houston venture capital and innovation

guest column

With fossil fuels facing an uncertain future, Houston is wisely pushing to further develop its innovation economy with initiatives like Houston Exponential and Rice Management Company's Ion, as well as the No. 1 ranked entrepreneurship programs at the University of Houston (undergraduate) and Rice (graduate).

Venture capital is both the critical fuel and limiting factor to expanding Houston's innovation ecosystem, but the vast majority of venture capital in this country is focused outside of Houston in places like Silicon Valley and Austin. How can we increase the local pool of venture capital focused on Houston?

A recent federal guidance provides the answer with a new option for adding dramatically to Houston's venture capital resources. On June 3rd 2020, the Department of Labor issued an information letter allowing 401k funds to invest in private equity, including venture capital. Houston has hundreds of thousands of employees contributing to 401k retirement plans, including those working at our 41 Fortune 1000 companies as well as other major employers like the Texas Medical Center hospitals. If even a small fraction of their savings could be channeled into Houston-focused venture capital funds (or funds of funds like the HX Venture Fund), it could add hundreds of millions of dollars to Houston's startup ecosystem.

How would this work? While federal guidance does not allow direct private equity investments in 401k plans, it does allow private equity to be part of the mix in target date, target risk, or balanced funds offered. Imagine the creation of a "Houston Balanced Fund" focused on a portfolio of equities and bonds from Houston companies, local government bonds, and a 15 percent allocation to Houston-focused venture capital (the maximum allowed for illiquid assets). The fund would be a bet on a prosperous long-term future for Houston — something I think many Houstonians would enthusiastically add to their retirement portfolios. Once created, it could be added to the investment options in 401k employer plans all over the city.

As an example of the power of this model: if 100,000 employees — only 3 percent of 3 million jobs in the Houston metro — invested just $10,000 of their 401k portfolios into a Houston Balanced Fund with 15 percent allocated to venture capital, it would inject an additional $150 million dollars into the local venture capital pool to spur new innovations and companies that can be the future of Houston's economy — a 20 percent increase to the $715 million of venture capital invested in Houston in 2020. This new venture capital could be leveraged even more by focusing it on early-stage Houston startups that might have trouble attracting the attention of national VC firms. As they mature to Series B rounds and beyond, they should have no trouble bringing in capital from outside the region.

This is an opportunity for Houston to do something no other city has done — to be innovative with not just new ventures and technologies, but with how they're financed. We can be proactive pioneers fueling Houston's 21st-century innovation ecosystem.

------

Tory Gattis writes the Houston Strategies blog and is a Founding Senior Fellow with the Urban Reform Institute – A Center for Opportunity Urbanism.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings